-
Something wrong with this record ?
Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy
S. Forde, JD. Matthews, L. Jahangiri, LC. Lee, N. Prokoph, TIM. Malcolm, OT. Giger, N. Bell, H. Blair, A. O'Marcaigh, O. Smith, L. Kenner, S. Bomken, GAA. Burke, SD. Turner
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
AHF1
Alex Hulme Foundation
Alex Hulme Foundation
PubMed
32880915
DOI
10.1111/bjh.17043
Knihovny.cz E-resources
- MeSH
- Burkitt Lymphoma genetics pathology therapy MeSH
- Child MeSH
- Heterografts pathology MeSH
- Humans MeSH
- Disease Models, Animal MeSH
- Mice MeSH
- Tumor Cells, Cultured MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Neoplasm Transplantation MeSH
- Animals MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Male MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by a MYC translocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.
Central European Institute of Technology Masaryk University Brno Czech Republic
Children's Health Ireland at Crumlin Dublin Ireland
Christian Doppler Laboratory for Applied Metabolomics Vienna Austria
Department of Life Sciences Birmingham City University Birmingham UK
Department of Paediatric Oncology and Haematology Addenbrooke's Hospital Cambridge UK
Department of Pathology Medical University of Vienna Vienna Austria
Northern Institute for Cancer Research Newcastle University Newcastle upon Tyne UK
Unit of Laboratory Animal Pathology University of Veterinary Medicine Vienna Vienna Austria
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019502
- 003
- CZ-PrNML
- 005
- 20210830101102.0
- 007
- ta
- 008
- 210728s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.17043 $2 doi
- 035 __
- $a (PubMed)32880915
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Forde, Sorcha $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
- 245 10
- $a Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy / $c S. Forde, JD. Matthews, L. Jahangiri, LC. Lee, N. Prokoph, TIM. Malcolm, OT. Giger, N. Bell, H. Blair, A. O'Marcaigh, O. Smith, L. Kenner, S. Bomken, GAA. Burke, SD. Turner
- 520 9_
- $a Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by a MYC translocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a Burkittův lymfom $x genetika $x patologie $x terapie $7 D002051
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a heterografty $x patologie $7 D064593
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a transplantace nádorů $7 D009368
- 650 _2
- $a nádorové buňky kultivované $7 D014407
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Matthews, Jamie D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
- 700 1_
- $a Jahangiri, Leila $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK $u Department of Life Sciences, Birmingham City University, Birmingham, UK
- 700 1_
- $a Lee, Liam C $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
- 700 1_
- $a Prokoph, Nina $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
- 700 1_
- $a Malcolm, Tim I M $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
- 700 1_
- $a Giger, Olivier T $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
- 700 1_
- $a Bell, Natalie $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Blair, Helen $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a O'Marcaigh, Aengus $u Children's Health Ireland at Crumlin, Dublin, Ireland
- 700 1_
- $a Smith, Owen $u Children's Health Ireland at Crumlin, Dublin, Ireland
- 700 1_
- $a Kenner, Lukas $u Department of Pathology, Medical University of Vienna, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria $u Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria
- 700 1_
- $a Bomken, Simon $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK $u The Great North Children's Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK $u Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Burke, Gladstone A A $u Department of Paediatric Oncology and Haematology, Addenbrooke's Hospital, Cambridge, UK
- 700 1_
- $a Turner, Suzanne D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 192, č. 2 (2021), s. 354-365
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32880915 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101102 $b ABA008
- 999 __
- $a ok $b bmc $g 1690348 $s 1139948
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 192 $c 2 $d 354-365 $e 20200903 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- GRA __
- $a AHF1 $p Alex Hulme Foundation
- GRA __
- $p Alex Hulme Foundation
- LZP __
- $a Pubmed-20210728